Shares of Indivior PLC (LON:INDV – Get Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 1,238 and traded as low as GBX 1,230. Indivior shares last traded at GBX 1,238, with a volume of 8,457,898 shares traded.
Indivior Stock Performance
The stock has a 50-day moving average of GBX 1,238 and a 200 day moving average of GBX 1,238. The company has a debt-to-equity ratio of -141.86, a current ratio of 0.90 and a quick ratio of 1.52. The stock has a market capitalization of £1.93 billion, a price-to-earnings ratio of -1,026.48, a price-to-earnings-growth ratio of -5.57 and a beta of 0.19.
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.
Recommended Stories
- Five stocks we like better than Indivior
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
